READ. SCROLL. LISTEN.

Unbiased headlines. Facts, not spin.

Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.

← Back to headlines

Trump Team Weighs Sen. Roger Marshall for FDA Post After Overton Exit, Officials Say; Acting Chief Diamantas Reportedly Considering Departure

Trump Team Weighs Sen. Roger Marshall for FDA Post After Overton Exit, Officials Say; Acting Chief Diamantas Reportedly Considering Departure
With Heidi Overton's nomination pulled and the committee vote set for today, Nov. 18, now moot, the White House is looking for a successor. Sen. Roger Marshall, who lost his reelection bid this month, is being discussed, and a Trump administration official says acting Commissioner Kyle Diamantas may leave regardless. The FDA has had no Senate-confirmed leader since May, and the window to confirm one closes when Democrats take the Senate in January.

Since President Trump nominated Dr. Heidi Overton in August, her path to FDA commissioner has run through skeptical Republicans, and the White House ended it Tuesday, Nov. 17, a day before the Senate HELP Committee was due to vote. The fight now is over who runs the agency next, and whether anyone can be confirmed in time.

Marshall Emerges as the Name to Beat

Semafor reported Tuesday that four people familiar with the discussions say Republicans are talking about Sen. Roger Marshall of Kansas as a replacement. Two sources told CBS News that Marshall, a physician, is making a play for the job himself.

Marshall sits on the HELP Committee. He lost his reelection bid this month to Democrat Adam Hamilton. His office declined to comment, and the White House has not named a new nominee.

The logic is about arithmetic, not medicine. "Marshall is viewed as an alternative if Heidi can't make it through," a Trump administration official told Semafor. "Senators have an easier time getting confirmed, traditionally. At this point, it's hard to get anyone approved."

A senior Republican aide told Semafor there is "a growing view in the Senate that a senator would be the only person while we've got a majority."

A Closing Window

Democrats take control of the Senate in January. Any commissioner needing confirmation has to clear committee and the floor before then.

Sen. Bill Cassidy, R-La., the outgoing HELP chair, told CBS News that "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."

Chris Meekins, a Raymond James healthcare analyst who worked at HHS during Trump's first term, predicted the agency will not have a permanent leader anytime soon. That, he said, "inevitably creates uncertainty." He added: "Had the White House heeded warnings by many before and after her nomination, they could have avoided this unfortunate outcome."

Before the withdrawal, the White House had already begun talking to other candidates, according to a source who spoke to CBS News. Some could serve in an acting capacity and skip Senate confirmation entirely.

The Acting Commissioner Question

Kyle Diamantas, an attorney and the former top food official at the agency, has run the FDA since Dr. Marty Makary was forced out in May. Makary's exit followed a dispute with the White House over authorizing flavored vaping products and pressure from anti-abortion Republicans seeking more restrictions on mifepristone.

A Trump administration official told Semafor that Diamantas did not want the permanent job and is weighing leaving the agency whatever happens with Overton's replacement. Semafor also reported that Diamantas has a reputation as a competent administrator who helped stabilize the agency. The White House has not commented on his plans.

If he leaves, an agency with more than 18,000 employees would need yet another stopgap. The FDA regulates products that account for roughly 20% of U.S. consumer spending.

Two Accounts of Why It Collapsed

The White House line, from a senior administration official speaking to Axios, is that the nomination was dropped for lack of congressional support. "We need to go in a new direction at FDA," the official said, adding that everyone "fully supports Secretary Kennedy's vision to Make America Healthy Again."

Cassidy rejects the premise. "Tonight, the White House abandoned a viable confirmation path for Dr. Overton," he wrote on X. He said he had been "having productive conversations with members" and believed she "would have had the votes to pass out of committee and pass the full Senate."

His explanation: "Pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues. The Administration withdrew Dr. Overton rather than make such commitments." The White House did not immediately respond to that claim.

CNN, citing a White House official and two other people familiar with the matter, reported that Trump officials had spent recent days trying to head off a threat from Sen. Josh Hawley and the anti-abortion movement. Those sources said the movement was angry at the administration's lack of urgency on restricting mifepristone distribution. Sens. Susan Collins and Lisa Murkowski had their own concerns, including over Overton's role in approving flavored vapes.

Overton needed 11 votes on the 21-member committee. If every Democrat opposed her, she could not lose a single Republican.

The pressure came from the MAHA side too. Supporters of HHS Secretary Robert F. Kennedy Jr.'s agenda opposed her, arguing she would not sufficiently challenge corporate interests. Sources told CNN her relationship with Kennedy was "icy." Overton was also seen as close to Susie Wiles, who left her post as White House chief of staff earlier this month, according to CBS News.

What Comes Next

The open questions are specific. The White House has not said whether it will send Marshall's name to the Senate, pick someone else, or install an acting leader. Diamantas has not said whether he is staying.

A Marshall nomination would need to move through the HELP Committee he sits on, with Cassidy still chairing it, in the few weeks before the gavel changes hands.

Sources used for this briefing

8 links from 8 independent newsrooms (syndicated copies of the same report count once)

These are the sources it draws on, linked so you can verify.

center
SemaforWhite House pulls Overton’s FDA nomination
center-left
AxiosScoop: White House drops Heidi Overton's FDA nomination
center-left
Yahoo NewsWhite House drops its nomination for FDA commissioner
center-left
CBS NewsWhite House drops its nomination for FDA commissioner
center-left
NBC NewsWhite House drops Heidi Overton’s FDA nomination after Republicans raise concerns
left
CNNWhite House drops Trump’s FDA pick amid senators’ opposition and ‘icy’ relationship with RFK Jr. | CNN Politics
left
MS NOWWhite House withdraws FDA nominee Heidi Overton amid GOP opposition
right
BreitbartReport: White House Drops Heidi Overton's FDA Nomination as Roger Marshall Emerges as Potential Replacement